Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Annovis Bio Inc (NY: ANVS )

6.790 +0.250 (+3.82%)
Official Closing Price Updated: 7:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Annovis Bio Inc

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging
Berwyn, Pennsylvania--(Newsfile Corp. - April 28, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug... 
Via Newsfile
Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease
Berwyn, Pennsylvania--(Newsfile Corp. - April 11, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug... 
Via Newsfile
Annovis Bio to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest
Berwyn, Pennsylvania--(Newsfile Corp. - March 23, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug... 
Via Newsfile
Annovis Bio Presents at International Conference on Alzheimer's & Parkinson (AD/PD 2022)
Berwyn, Pennsylvania--(Newsfile Corp. - March 18, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug... 
Via Newsfile
Annovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022
Berwyn, Pennsylvania--(Newsfile Corp. - March 8, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug... 
Via Newsfile
Annovis Bio to Present at the Cowen 42nd Annual Health Care Conference
Berwyn, Pennsylvania--(Newsfile Corp. - March 3, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug... 
Via Newsfile
FDA Guides Annovis Bio For Two Phase 3 Buntanetap Trial In Parkinson's Disease
Annovis Bio Inc (NYSE: ANVS) has completed a Type B meeting with the FDA regarding its planned Phase 3 studies of Buntanetap for the treatment of Parkinson's... 
Via Benzinga
Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease
Berwyn, Pennsylvania--(Newsfile Corp. - January 25, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug... 
Via Newsfile
Exposures Product Safety
Annovis Bio Enhances Leadership Team with Two Senior Appointments
Company Appoints Eve Damiano, MS, RAC, as Senior Vice President of Regulatory OperationsCompany Promotes Cheng Fang, Ph.D., to Senior Vice... 
Via Newsfile
Annovis Bio Announces Official Unique Name Buntanetap for Lead Candidate ANVS401
Berwyn, Pennsylvania--(Newsfile Corp. - January 5, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug... 
Via Newsfile
Annovis Bio to Participate in the Biotech Showcase and H.C. Wainwright Bioconnect Virtual Conferences
Berwyn, Pennsylvania--(Newsfile Corp. - January 3, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug... 
Via Newsfile
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers OptiNose (NASDAQ:OPTN) shares mov... 
Via Benzinga
Annovis Bio on Its Positive Results in Alzheimer's and Parkinson's Clinical Trials
Image provided by Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... 
Via Benzinga
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
Berwyn, Pennsylvania--(Newsfile Corp. - December 20, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage... 
Via Newsfile
Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics
Berwyn, Pennsylvania--(Newsfile Corp. - December 14, 2021) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug... 
Via Newsfile
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Lixte Biotech Holdings (NASDAQ:LIXT 
Via Benzinga
Annovis Bio Presented At The 14th Clinical Trials on Alzheimer's Disease Conference
Berwyn, Pennsylvania--(Newsfile Corp. - November 12, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage... 
Via Newsfile
Exposures Product Safety
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded... 
Via Benzinga
Annovis Bio Presents Poster on Mechanism of Action at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference
Berwyn, Pennsylvania--(Newsfile Corp. - November 9, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage... 
Via Newsfile
SHAREHOLDER ALERT: Robbins LLP Investigates Annovis Bio, Inc. (ANVS) for Misleading Shareholders
From Robbins LLP
Via Business Wire
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
Annovis Bio to Present at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference
Dr. Maria Maccecchini will present additional Phase 2 data on November 12, 10:25 a.m. ESTA poster highlighting the mechanism of... 
Via Newsfile
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
Why Cortexyme Thinks It Could Be Next In The Mega Alzheimer's Drug Market
Cortexyme is testing a twice-day pill to treat Alzheimer's disease. 
Via Investor's Business Daily
92 Biggest Movers From Friday
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares jumped 99.8% to close at $9.99 on Friday. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the... 
Via Benzinga
MONDAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Annovis Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ANNOVIS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Annovis Bio, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
44 Biggest Movers From Yesterday
Gainers Benessere Capital Acquisition Corp. (NASDAQ: BENER) shares jumped 66.5% to close at $0.4530 on Thursday. Grove, Inc. (NASDAQ: GRVI) gained 39.3% to close at $6.98 after... 
Via Benzinga
DEADLINE MONDAY ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Annovis Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.